BEAT-MS: AHSCT versus best available therapy in resistant relapsing MS
Published by MyelinWatch:
BEAT-MS: AHSCT versus best available therapy in resistant relapsing MS · BEAT-MS compares an AHSCT strategy—intensive immune suppression followed by a person's own blood-forming stem cells—with best available disease-modifying therapy in resistant relapsing MS.
What is being studied
BEAT-MS compares an AHSCT strategy—intensive immune suppression followed by a person's own blood-forming stem cells—with best available disease-modifying therapy in resistant relapsing MS.
Research stage
Large study to confirm benefit and safety
The current listing is open to participants.
What we know so far
The Phase 3 registry protocol compares two approaches and lists the study as accepting participants; the cited registry record has no posted outcome results.
What this means for patients today
This comparison does not yet tell an individual whether transplantation would help. Eligibility and current places belong to the study team; AHSCT risks need specialist discussion.
- Treatment or approach
- BEAT-MS: AHSCT versus best available therapy in resistant relapsing MS
- Where the study is running
- The registry lists no Greek study location; this is not proof that AHSCT is unavailable in Greece by other routes.
- Published by MyelinWatch
- Last substantive MyelinWatch update